Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
InfuSystems Q4 Earnings Up on Weaker Revenues
04:17 PM EDT, 03/09/2015 (MT Newswires) -- InfuSystems Holdings(INFU) , a provider of infusion pumps and related services, reported Monday a year-over-year increase in its Q4 2014 earnings on lower revenues versus the comparable period in 2013.
The company reported a net income for the quarter of $0.05 per share, up 25% from $0.04 per share in Q4 2013. Analyst estimates called for earnings of $0.05 per share, according to Capital IQ.
Revenues were $16.3 million, down slightly from $17.2 million reported for the same period last year and below expectations of $17.2 million.
For full year 2015, the company expects revenue to grow in the high single digit.
I love turd trading! Picked up another 350 turds @ $16.75. Have an order for 500 more turds @ $16.5! Will sell the sh$t back @ $20+!!!
Wow, made another $8K this morning and re-loaded this afternoon! I love this stock! I have another buy set @ $16.50, if it goes there.
Get ready for the next move! Should test $9!!!!
Woot, Woot!
Eric will take us to the promised land!
Better get a ticket!!!
My EYES will always be on this stock!
What a fun week!
I 1st bought into EYES on 11/19/14 @ $21.665/share. Watched it down to $14, then started buying again 12/17 @ $13.3873. My best buy was on 2/17 @ $8.923!
Sold all my sub $14 shares on Friday @ $17, then bought every 4% dip. I plan to continue to buy/sell on +/- 4% moves as long as I can.
I consider Friday 2/27, my grand-slam of day trading! Hope I hit another in my lifetime!!!
SELL! SELL! SELL!
Time to start the panic selling!
I could use some more shares on the cheap.
The time is near!
Better have a ticket!
Woot! Woot!
Timing is everything!
Timing is critical!
Not sure why this is down over 12% today, but I got in @ $2.54. Hope to take advantage of a bounce tomorrow?
WOOT! WOOT!
We have pulled away from Sub-Penny Land!
Next stop is Two-Cent Land!
Better buy your ticket why they are cheap!!!
I own over 3M shares and am very happy with my investment!
Woot, Woot!
All Aboard!
This is your chance to buy a ticket!
Woot, Woot!
You forgot one thing, you have to have a ticket! If you don't have a ticket, you can't ride the HHSE train!
Woot, Woot!
BONE up over 29% and halted trading!
I got out @ 3.94!!!
Done, Done, Done!!!
Woot, Woot!!
All Aboard!
Woot, Woot!!
All Aboard!
Cytokinetics Soars 19% as Q4 EPS Tops Views; Guides FY15 Revenue Mostly Above Street
10:31 AM EST, 02/13/2015 (MT Newswires) -- Shares of Cytokinetics Inc.(CYTK) soared Friday morning after the biopharmaceutical firm reported late Thursday better-than-expected Q4 earnings and guided full-year 2014 revenues in line to above consensus forecasts compiled by Capital IQ.
Q4 net income rose to $8.4 million, or $0.23 per share, from $6.5 million, or $0.21 per share, in the prior-year period, topping the average analyst estimate for a loss of $0.17 a share.
Revenue fell to $21.8 million from $24.3 million, which may not be comparable to the consensus of $10.8 million.
For FY15, CYTK expects cash revenue of between $40 to $43 million, mostly above expectations of $40 million. The guidance includes $30 million in revenue which will be deferred and recognized over a two-year period ending in 2016 on a GAAP-basis. The guidance excludes a $15 million milestone payment earned in 2014 from Astellas and an estimated $3.6 million in non-cash related operating expenses primarily related to stock compensation expense.
CYTK was up 19% at $7.73 in recent morning trade, still moving below the midpoint of the 52-week range of $3.05 to $13.26.
Price: 7.73, Change: +1.24, Percent Change: +19.10
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
That was a nice pop this morning, but there is still room to run! Not selling until this reaches $13!!!
Can't wait to see what CYTK does tomorrow! I loaded up @ $6.50!
SOUTH SAN FRANCISCO, CA, February 12, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013. The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share. This is compared to a net income for the same period in 2013, of $6.5 million, or $0.22 per basic share and $0.21 per diluted share. As of December 31, 2014, cash, cash equivalents and investments totaled $83.2 million, which includes the receipt of $10 million for the sale of common stock to Astellas Pharma Inc., but does not include $45.0 million received from Astellas in January 2015. With the recognition of a milestone payment under its collaboration agreement with Astellas, the company exceeded its 2014 financial guidance.
“The recent expansion of our collaboration agreement with Astellas enables Cytokinetics to advance CK-2127107 into a Phase II trial in 2015 as well as the financial leverage to capitalize on other pipeline progress,” stated Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “Regulatory interactions over the last few months in both the United States and Europe inform a path forward for tirasemtiv to Phase III in patients with ALS. In addition, we are nearing completion of enrollment in COSMIC-HF, enabling the reporting of key data relating to omecamtiv mecarbil in chronic heart failure patients later this year. Taken all together, we have entered 2015 well positioned to achieve on program milestones relating to our first-in-class drug candidates directed to augmenting muscle function across multiple therapeutic categories.”
The Terminator series is an American science fiction franchise encompassing a series of films and additional media concerning battles between Skynet's artificially intelligent machine network, and John Connor's Resistance forces and the rest of the human race. Skynet's most well-known products in its genocidal goals are the various terminator models, such as the original "Terminator" character, who was portrayed by Arnold Schwarzenegger from the first film, and similar units he also portrayed in the later films. The fifth film in the franchise, Genisys, is set for release in 2015.
Eric put his Superman cape away months ago!
Couldn't agree more!
BONE up almost 9.5% today!
• Solid foundation for accelerating growth in 2015 and beyond
• Growing team of Field Sales assets
• New Product Pipeline
• Path to EBITDA profitability and positive cash flow
4th Consecutive Quarter of Year-over-Year Growth
• 3Q14 Revenues increased 6.6% over 3Q13
• Four consecutive quarters of YoY growth
• Improving Gross Profit and Gross Margins
• Narrowing Operating Loss
• Investing in New Products and Sales Assets
http://investor.bacterin.com/phoenix.zhtml?c=234008&p=irol-investorkit
Carl Icahn says Apple is still undervalued, plans to increase his $203 price target!
http://appleinsider.com/articles/15/01/28/carl-icahn-says-apple-is-still-undervalued-plans-to-increase-his-203-price-target
PANIC SELLING!
Please sell some more!
Happy New Year!!!!
I am proud to say that I do support Eric and appreciate everything he is trying to do! If it were easy, anybody would do it! Perhaps I have a little more patience than most?
Woot, woot!
Train has left the station!
Good day to add some shares!
Thanks for the dip!!!
Up over 30% so far this week!
Closes over $8!
Can't wait till Friday!!!
2015 is the year of the solar dog house!!!
Go EXPH!!!!
$8 and counting!!!
$8 today would be great, but still well short of our new $18 target price! This will be a fun ride!!!
Up almost 20% since your Ha ha!
Ho ho back at you! Hope your in, cause we have a ways to go!!!
Up another 3.45% today (12/30/14)!
More than double since 10/9/14!!!
Cytokinetics carries a Zacks Rank #1 (Strong Buy).
Cytokinetics also has collaborations with Amgen Inc. (AMGN).
As per the amemded agreement, Cytokinetics will be receiving $55 million from Astellas. This $55 million includes a $30 million upfront license fee, $10 million for Astellas’ purchase of Cytokinetics’ common stock and another $15 million as milestone payment in relation to Astellas’ decision to advance CK-2127107 into phase II clinical development which is expected in 2015.
Additionally, Cytokinetics is expected to receive over $600 million as pre-commercialization and commercialization milestone payments including more than $100 million payable for CK-2127107 in SMA and other neuromuscular indications. Moreover, as per the deal, Cytokinetics is also eligible to receive escalating royalties.
ASTELLAS PHARMA INC. files Form SC 13G on 12/29/2014!
insert-text-here